Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The past few years have been a ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Forbes contributors publish independent expert analyses and insights. Vibhas Ratanjee studies leadership and culture at Gallup This voice experience is generated by AI. Learn more. This voice ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

67% of Gen Z and 66% of millennials own AI stocks, anticipating long-term positive market impacts. Millennials are the most bullish on AI's market benefits; 73% foresee strong returns over the next ...

Editor’s Note — March 2026: We’ve updated our story to make sure items are in stock and available, plus we added a new best overall, the Goal Zero 1500 power station, a new model we recently reviewed, ...